Skip to content
ClinCalc Pro
Menu
NMDA Receptor Antagonist (Dissociative Anaesthetic)

Ketamine (Burns Procedural Analgesia)

Brand names: Ketalar

Ketamine is a dissociative NMDA-receptor antagonist used to provide analgesia for painful burns procedures such as dressing changes and debridement.

Dosing — not shown for this use

The product information we hold does not support a dose for this page's specific use, route or population, so none is shown. Follow your local or national guideline, and confirm against the product SmPC.

The licensed dosing — for the medicine's licensed uses, which may differ from this page's — is on Ketamine.

Clinical monograph

How it works

It produces dissociative analgesia and anaesthesia mainly by non-competitive antagonism of the NMDA glutamate receptor, with relative preservation of airway reflexes and respiratory drive at analgesic levels.

Prescribing in practice

  • Use only with appropriate monitoring and staff trained in airway management and resuscitation, as emergence phenomena, hypersalivation and, with rapid or high dosing, respiratory and cardiovascular effects can occur.
  • It raises blood pressure and heart rate and should be used cautiously in uncontrolled hypertension or significant cardiac disease.
  • Co-administered benzodiazepines can attenuate distressing emergence reactions but add to sedation, requiring vigilant observation.

Monitoring

Monitor conscious level, airway, oxygen saturation, and cardiovascular parameters throughout the procedure and into recovery.

Counselling the patient

  • You may feel detached, dreamlike or experience vivid imagery during the procedure, which wears off as the drug leaves your system.
  • Do not drive or make important decisions for the remainder of the day after sedation.

Evidence & guidelines

Ketamine is a long-established agent for procedural analgesia and sedation, valued in burns care for analgesia with relative cardiorespiratory stability.

Reference: BBA guidelines; PERN study; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.